Ribavirin plus interferon versus interferon for chronic hepatitis C

Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals

“…Prevalence of HCV infection in PCT cases varies geographically Lichen planus [7] Strongly correlated with HCV infection in meta-analysis Localized reactions Erythematous or eczematous dermatitis and psoriasis [16,19] Localized alopecia associated with local cutaneous reactions to interferon [20] Skin ulceration and necrosis [21] Local infections and local allergic reactions to interferon injection [16] Generalized reactions Alopecia/hair growth anomalies [16] Skin xerosis, dermatitis and pruritus [16,22] skin, such as lichen planus or psoriasis, Chronic inflammatory diseases of the which may be induced or exacerbated by interferon [16,19] Autoimmune disorders and immune-mediated inflammatory disease (e.g. psoriasis and sarcoidosis) [23,24] 1.62, 95% CI 1.29-2.02), and rash (RR 1.74, 95%CI 1.17-2.61), as demonstrated in a recent Cochrane meta-analysis [25]. Dermatological adverse events with peginterferon/ribavirin combination therapy tend towards a uniform entity of dermatitis, characterized by generalized pruritus and skin xerosis, with eczematiform lesions accentuated by erythematous papules and microvesicles that are often excoriated, predominantly located on the extremities and on truncal skin sites exposed to friction [22].…”

Direct Medical Care Costs Among Pegylated Interferon Plus Ribavirin-Treated and Untreated Chronic Hepatitis C Patients

“…Despite the previous consensus [6] that this majority of patients has asymptomatic seropositivity, evolving data now indicate that HCV itself may diminish quality of life in the absence of liver disease, perhaps as a result of extra-hepatic symptoms related to HCV [5]. Taken together, these facts support the rationale for actively treating HCV in eligible subjects-a strategy that can be both effective [7,8] and cost-effective [9,10] when used appropriately.…”

Meta‐analysis: antioxidant supplements for liver diseases – the Cochrane Hepato‐Biliary Group

“…Improved sustained virological response does not definitely mean significant improvement in clinical outcomes. 64,65 The use of new interventions in hepatology should not be justified until these have been proven to be beneficial on clinical outcomes. 66,67 The increase in the number of hepato-biliary randomized trials will never be considered a sufficient valuable source for data if aspects of the trial design, like sample size, completeness of data reporting, duration of follow-up and bias risk, are not improved, and trial performance and reporting do not follow the CONSORT guidelines.…”